Post-depletion lymphocyte repertoire composition favoring belatacept susceptibility

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement

The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increa

Effect: improvement